PROJECT OUTLINE

• This biotech proposes an ambitious strategy for the development and production of an inactivated and adjuvanted SARS-CoV-2 vaccine.
• It is negotiating with various governments in Europe and across the Atlantic, as well as with international organizations (WHO | COVAX).
• The mastery of the business case is essential to the negotiations of price and financing of the project (clinical development, production capacity, etc.).
• Pagamon builds the business plan and conducts the associated analyses.

PROJECT APPROACH

• Handling of the initial financial model.
• Review of financial and operational assumptions with the program’s stakeholders: pre-clinical and clinical R&D, CAPEX, product development, process, bio-production, filling, packaging, quality control…
• Preparation of scenarios for the Management Committee and the Supervisory Board.
• Analysis of clinical, production and financial risks: yields, success rates, clinical results, payment schedule, etc.
• Construction of a financial model capable of managing multiple successive or parallel contracts as well as various clinical and industrial options.

RESULTS

• Modeling of costs and cash flows for each scenario.
• Supported negotiations with public authorities for their “at risk” national pre-orders of doses.
• Analysis and recommendations for the Management Committee and the Supervisory Board.
• This biotech has signed a contract with the UK government for the supply of 60 million doses for €470 million, with options to supply an additional 130 million doses.